Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, Genomac Expand Cancer Collaboration

NEW YORK (GenomeWeb) – Trovagene today announced the expansion of a clinical collaboration with Genomac Research Institute using the company's technology for the early detection of emerging oncogene mutations associated with resistance to targeted lung and colorectal cancer therapies. 

As part of the expanded collaboration, researchers at Genomac will use the Trovagene Precision Cancer Monitoring technology in two prospective clinical studies to be conducted in the Czech Republic. The first study will focus on lung cancer and enroll up to 300 patients. The second study of stage III and IV colorectal cancer will enroll up to 500 patients. 

Trovagene CSO Mark Erlander said in a statement that initial work into KRAS mutations in archived samples are promising and the clinical program is being expanded "to demonstrate the utility of our novel molecular diagnostic platform and its potential to improve the standard of care for cancer patients." 

Trovagene's technology isolates cell-free nucleic acids from urine for downstream analysis using platforms such as droplet-based digital PCR and next-generation sequencing. 

Marek Minarik, lead investigator and director of the Center for Applied Genomics of Solid Tumor, a subsidiary of Genomac International, added that oncogene mutations associated with anti-EGFR treatment resistance, including KRAS and EGFR T790M, are the primary cause of disease progression after initial positive response to first-line colorectal and lung cancer treatments. Trovagene's technology could "become a viable alternative to standard imaging techniques, aiding timely decision on the course of therapy made by our clinical partners."

  

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.